Established in 2000, Zota is a renowned Indian pharmaceutical company with a diverse portfolio that includes pharmaceutical, nutraceutical, and ayurvedic products. Committed to innovation and affordability, Zota is listed on the NSE and operates both domestically in India and internationally, with a presence in countries like Sri Lanka, Vietnam, and Nigeria.
Zota Health Care Limited has recently achieved an important milestone by securing product registration licences for twelve of its pharmaceutical offerings from the Department of Pharmaceutical Administration in Vietnam.
This development marks a significant advancement for the company as it expands into the Vietnamese market. The approved products encompass various therapeutic categories, including angiotensin II antagonists, NSAIDs, antibiotics, and anti-hyperlipidemic agents, enabling Zota to cater to the increasing demand for a wide range of healthcare solutions in the region.
Among the twelve licenced products are popular medications such as Telmisartan, Etoricoxib, Levofloxacin, and Rosuvastatin. These products have received approval for a five-year period, with the option for renewal once this term expires. The company intends to commence exports of these products to Vietnam soon, thereby enhancing its international presence.
The registration of these products highlights Zota Health Care’s dedication to enhancing its global footprint and addressing the evolving healthcare requirements in international markets. The company intends to leverage this success by presenting its extensive portfolio to the Vietnamese market, where there is a growing demand for high-quality pharmaceutical products.
As of 3:00 PM, Zota Health Care Ltd. shares are trading at ₹655.55 on the NSE, reflecting an increase of over 2% today. The stock’s highest price over the past 52 weeks was ₹725.05, while the lowest price recorded during that period was ₹440.10.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
We're Live on WhatsApp! Join our channel for market insights & updates